Hemostemix Signs Manufacturing Agreement with Aspire Health Science

Hemostemix (TSXV:HEM) is pleased to announce it has finalized the terms of a contract manufacturing services agreement with Aspire Health Science, LLC underpinning the previously announced transition of the Company’s stem cell manufacturing operations from Company owned facilities in Israel to a third party operator in North America.

As quoted in the press release:

Angus Jenkins, Chair of the Board of Hemostemix noted: “After careful evaluation, Aspire was clearly the best fit for our current objectives. The agreement allows Hemostemix to streamline the production of ACP-01 for our current trials, while ensuring the highest quality is maintained in a regulated and certified lab.  Aspire’s lab has undergone strict testing to ensure that all the FDA requirements and clinical trial protocols can be executed with the highest quality standards.”

Click here to read the full press release.